Expert insights. Personalized for you.
Clinical Trials Related Topics 
Veriheal
JUNE 17, 2021
However, there has not been a clinical trial assessing the efficacy of cannabis for migraines, at least not until now. Science Alert has announced that the first clinical trial for cannabis as a migraine treatment is underway.
NORML
FEBRUARY 25, 2020
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
FEBRUARY 16, 2021
“This study demonstrates that treatment with THC-rich cannabis in patients with mild to moderate UC is associated with clinical improvement.". The post Clinical Trial: Cannabis Inhalation Associated with Clinical in Patients with Ulcerative Colitis appeared first on NORML.
NORML
FEBRUARY 4, 2021
“In this study, we have demonstrated for the first time in a placebo-controlled trial that cannabinoid treatment has the potential to decrease disruptive behaviors associated with ASD, with acceptable tolerability.".
NORML
OCTOBER 30, 2020
The post Clinical Trial: Plant-Derived Cannabis Oil Effective for Patients with Fibromyalgia appeared first on NORML. "We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients.".
NORML
MAY 21, 2019
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. In clinical models, CBD administration has been shown to reduce cravings for tobacco. Investigators at The Mount Sinai Health System in New York City assessed the effect of CBD versus placebo in 42 drug-abstinent participants with a history of heroin use.
Cannabis Law Report
MAY 26, 2021
MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects of serotonergic hallucinogen mescaline have… Read More.
Cannabis Life Network
NOVEMBER 18, 2020
announced early this morning that it will undertake a clinical trial of psilocybin-assisted psychotherapy. About the Research & Clinical Trial Numinus Wellness […]. Vancouver based Numinus Wellness Inc.
Cannabis Life Network
OCTOBER 14, 2021
Even as a common name, CBG had yet to undergo the same tests and clinical trials as CBD to ensure high doses are safe. The post CBG is safe, gets green light for clinical trials and therapy appeared first on Latest Cannabis News Today - Headlines, Videos & Stocks.
NORML
DECEMBER 9, 2020
The post House Passes Bipartisan Bill Facilitating Clinical Cannabis Research, Allowing Scientists to Access State-Approved Marijuana Products appeared first on NORML. LEGISLATION Research SCIENCE clinical trials DEA House vote research University of Mississippi
Cannabis Law Report
FEBRUARY 22, 2021
The post Psychedelic Clinical Trials & Who’s Behind Them first appeared on Cannabis Law Report. CFN report… The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging… Read More.
|
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The Principal Investigator for the trial will be Kevin Boehnke, Ph.D.,
Cannabis Law Report
JUNE 7, 2021
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. POTOMAC, Md.–(BUSINESS
Cannabis Law Report
AUGUST 10, 2021
Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.
Cannabis Law Report
FEBRUARY 27, 2022
has secured Clinical Trial Authorisation (CTA) with Health Canada. The CTA positions Halucenex as one of the few companies in Canada with clearance to begin a clinical trial utilising psychedelic substances.
Cannabis Law Report
AUGUST 24, 2021
Nasdaq:HUGE) (CSE:HUGE) (FRA:0K9) (the “ Company ” or “ FSD ”) announced today that it intends to terminate the Phase 2 clinical trial of ultra-micronized palmitoylethanolamide (“PEA”), or FSD-201, for use in treating COVID-19.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin.
Cannabis Law Report
MAY 11, 2021
Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial. VANCOUVER, BC, May 11, 2021 /CNW/… Read More. Cannabis Finance News
Cannabis Law Report
JANUARY 17, 2021
The post NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials first appeared on Cannabis Law Report. We hope he does a better job than some of the playlists we’ve seen recently ! NeonMind Biosciences Inc. … Read More.
Cannabis Law Report
OCTOBER 6, 2021
NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally.
Cannabis Law Report
MARCH 25, 2022
The trial, which was conducted jointly at NYU Langone and Baptist Health/Jacksonville Orthopaedic Institute and led by Principal Investigator Dr. Michael J. EWING, N.J.–(BUSINESS –(BUSINESS WIRE)– Orcosa Inc.
Veriheal
MAY 3, 2022
The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size.
Cannabis Law Report
DECEMBER 13, 2020
Clinical trials on the hallucinogenic drug DMT for the treatment of depression are expected to start in January. The post UK: Imperial College Of London To Study DMT In First-Ever Clinical Trial first appeared on Cannabis Law Report. Yahoo Finance Reports.
Cannabis Law Report
MAY 17, 2022
–(BUSINESS WIRE)–The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc announce a collaboration in a new clinical trial investigating treatment for adults with Post-Traumatic Stress Disorder (PTSD). Clinical Trials.gov Identifier NCT05269459 ).
Cannabis Law Report
JUNE 1, 2021
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain.
Cannabis Life Network
OCTOBER 22, 2021
Featured Health & Sex Interview Marijuana News Psychedelics News ayahuasca clinical trials Delic delic corp ketamine legal lsd magic mushrooms matt stang mdma mental health mushrooms psilocybin psychedelic therapy psychedelics
Cannabis Law Report
JUNE 29, 2021
As a member of Ehave’s Medical Advisory Board, Dr. Desai’s main responsibilities will be to assist and advise the Company on human trials for its cognitive and psychedelic opportunities, as well as assist and advise the Company on mental health analytical platforms.
Cannabis Law Report
OCTOBER 26, 2021
The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. If these trials are successful and IHL-42X is approved for the market, Procaps will also make IHL-42X for patients.
NORML
DECEMBER 6, 2019
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Polish investigators conducted a randomized, double-blind placebo-controlled trial assessing the efficacy of twice-daily transdermal CBD administration on 60 patients with TMD over a period of 14 days.
Cannabis Law Report
JULY 19, 2021
There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.
Cannabis Law Report
FEBRUARY 10, 2022
Radicle Science launches several blinded placebo-controlled clinical trials on rare cannabinoids with 10,000 participants in the first half of 2022 on the heels of completing 25 large-scale CBD studies in 2021.
Cannabis Law Report
MARCH 30, 2019
The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. Japanese officials approve Epidiolex for clinical trials.
Cannabis Law Report
DECEMBER 14, 2021
IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. POTOMAC, Md.–(BUSINESS
Cannabis Law Report
APRIL 7, 2022
RLS will use the proceeds from the financing to advance RLS103 through proof-of-concept clinical safety and efficacy studies.
Cannabis Law Report
JANUARY 4, 2022
Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.
Cannabis Law Report
APRIL 1, 2022
We are pleased to announce the successful dosing of more than half of the subjects in Part A of our ongoing Phase 2 clinical trial, a study designed to evaluate the safety and effectiveness of ANEB-001 in treating ACI,” said Simon Allen, Chief Executive Officer of Anebulo.
Cannabis Law Report
APRIL 12, 2021
– Vaccine Candidate Well Tolerated and Effective in Cohort – – Strong Neutralizing Antibody Titer Elicited Across Cohort – STONY… Read More. Business Wire
68 
Let's personalize your content